Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma

Kenji Inoue,1 Junji Inoue,2 Shiho Kunimatsu-Sanuki,2 Norie Nozaki,3 Kosuke Shimizu,4 Kyoko Ishida,5 Goji Tomita1,5 1Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan; 2Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan; 3Omiya Inouye Eye Clinic, Saitama-Shi, Saitama, Japan; 4Sapporo Inouye Eye Cli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Inoue J, Kunimatsu-Sanuki S, Nozaki N, Shimizu K, Ishida K, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	intraocular pressure adverse reactions ep2 receptor agonist conjunctival hyperemia Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/cc5742bfe4e54d69a1595ed7dd640374
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc5742bfe4e54d69a1595ed7dd640374
record_format	dspace
spelling	oai:doaj.org-article:cc5742bfe4e54d69a1595ed7dd6403742021-12-02T12:39:34ZShort-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma1177-5483https://doaj.org/article/cc5742bfe4e54d69a1595ed7dd6403742020-09-01T00:00:00Zhttps://www.dovepress.com/short-term-efficacy-and-safety-of-omidenepag-isopropyl-in-patients-wit-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kenji Inoue,1 Junji Inoue,2 Shiho Kunimatsu-Sanuki,2 Norie Nozaki,3 Kosuke Shimizu,4 Kyoko Ishida,5 Goji Tomita1,5 1Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan; 2Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan; 3Omiya Inouye Eye Clinic, Saitama-Shi, Saitama, Japan; 4Sapporo Inouye Eye Clinic, Sapporo-Shi, Sapporo, Japan; 5Department of Ophthalmology, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, JapanCorrespondence: Kenji InoueInouye Eye Hospital, Chiyoda-Ku, Tokyo, JapanTel +81 03 3295 0911Fax +81 03 3295 0917Email 2inoue-k@inouye-eye.or.jpPurpose: To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG).Patients and Methods: Fifty-four NTG patients (54 eyes) who were newly administrated with omidenepag isopropyl were enrolled in the study. The subjects comprised 22 men and 32 women, and the mean age of the subjects was 55.0 ±  14.1 years. The mean deviation value using the Humphrey visual field test program (30– 2 SITA Standard) was − 5.03 ±  3.38 dB. The following data were retrieved from the medical records and used for retrospective analyses: IOP at baseline 1– 2 months and 3– 4 months after administration. The frequency of non-responder patients who had less than 10% IOP reduction was evaluated. Patients were observed for adverse reactions and dropouts at each time point.Results: IOP at baseline, after 1– 2 months and after 3– 4 months was 15.7 ±  2.6 mmHg, 13.5 ±  2.3 mmHg, and 13.6 ±  2.4 mmHg, respectively. There was a significant decrease in IOP after administration (p< 0.0001). Eleven patients (22.4%) were non-responders. Adverse reactions occurred in 4 patients (7.4%), including conjunctival hyperemia in 3 patients (after 1 week, 2 weeks, and 1 month, respectively) and eye pain in 1 patient (after 1 month). Five patients (9.3%) dropped out of the study because of an adverse reaction in 3 patients, insufficient IOP reduction in 1 patient, and discontinuation of follow-up of 1 patient at our institution.Conclusion: After administration of omidenepag isopropyl, IOP in patients with NTG was significantly decreased. However, adverse reactions occurred in 7.4% of patients.Keywords: intraocular pressure, adverse reactions, EP2 receptor agonist, conjunctival hyperemiaInoue KInoue JKunimatsu-Sanuki SNozaki NShimizu KIshida KTomita GDove Medical Pressarticleintraocular pressureadverse reactionsep2 receptor agonistconjunctival hyperemiaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 2943-2949 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	intraocular pressure adverse reactions ep2 receptor agonist conjunctival hyperemia Ophthalmology RE1-994
spellingShingle	intraocular pressure adverse reactions ep2 receptor agonist conjunctival hyperemia Ophthalmology RE1-994 Inoue K Inoue J Kunimatsu-Sanuki S Nozaki N Shimizu K Ishida K Tomita G Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
description	Kenji Inoue,1 Junji Inoue,2 Shiho Kunimatsu-Sanuki,2 Norie Nozaki,3 Kosuke Shimizu,4 Kyoko Ishida,5 Goji Tomita1,5 1Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan; 2Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan; 3Omiya Inouye Eye Clinic, Saitama-Shi, Saitama, Japan; 4Sapporo Inouye Eye Clinic, Sapporo-Shi, Sapporo, Japan; 5Department of Ophthalmology, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, JapanCorrespondence: Kenji InoueInouye Eye Hospital, Chiyoda-Ku, Tokyo, JapanTel +81 03 3295 0911Fax +81 03 3295 0917Email 2inoue-k@inouye-eye.or.jpPurpose: To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG).Patients and Methods: Fifty-four NTG patients (54 eyes) who were newly administrated with omidenepag isopropyl were enrolled in the study. The subjects comprised 22 men and 32 women, and the mean age of the subjects was 55.0 ±  14.1 years. The mean deviation value using the Humphrey visual field test program (30– 2 SITA Standard) was − 5.03 ±  3.38 dB. The following data were retrieved from the medical records and used for retrospective analyses: IOP at baseline 1– 2 months and 3– 4 months after administration. The frequency of non-responder patients who had less than 10% IOP reduction was evaluated. Patients were observed for adverse reactions and dropouts at each time point.Results: IOP at baseline, after 1– 2 months and after 3– 4 months was 15.7 ±  2.6 mmHg, 13.5 ±  2.3 mmHg, and 13.6 ±  2.4 mmHg, respectively. There was a significant decrease in IOP after administration (p< 0.0001). Eleven patients (22.4%) were non-responders. Adverse reactions occurred in 4 patients (7.4%), including conjunctival hyperemia in 3 patients (after 1 week, 2 weeks, and 1 month, respectively) and eye pain in 1 patient (after 1 month). Five patients (9.3%) dropped out of the study because of an adverse reaction in 3 patients, insufficient IOP reduction in 1 patient, and discontinuation of follow-up of 1 patient at our institution.Conclusion: After administration of omidenepag isopropyl, IOP in patients with NTG was significantly decreased. However, adverse reactions occurred in 7.4% of patients.Keywords: intraocular pressure, adverse reactions, EP2 receptor agonist, conjunctival hyperemia
format	article
author	Inoue K Inoue J Kunimatsu-Sanuki S Nozaki N Shimizu K Ishida K Tomita G
author_facet	Inoue K Inoue J Kunimatsu-Sanuki S Nozaki N Shimizu K Ishida K Tomita G
author_sort	Inoue K
title	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
title_short	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
title_full	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
title_fullStr	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
title_full_unstemmed	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
title_sort	short-term efficacy and safety of omidenepag isopropyl in patients with normal-tension glaucoma
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/cc5742bfe4e54d69a1595ed7dd640374
work_keys_str_mv	AT inouek shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT inouej shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT kunimatsusanukis shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT nozakin shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT shimizuk shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT ishidak shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma AT tomitag shorttermefficacyandsafetyofomidenepagisopropylinpatientswithnormaltensionglaucoma
_version_	1718393827626057728

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma

Ejemplares similares